 | Up a level |
de Azambuja, E; Agostinetto, E; Procter, M; Eiger, D; Pondé, N; Guillaume, S; Parlier, D; Lambertini, M; Desmet, A; Caballero, C; Aguila, C; Jerusalem, G; Walshe, J M; Frank, E; Bines, J; Loibl, S; Piccart-Gebhart, M; Ewer, M S; Dent, S; Plummer, C; ... (2023). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO open, 8(1), p. 100772. BMJ 10.1016/j.esmoop.2022.100772
Jerusalem, G; Farah, S; Courtois, A; Chirgwin, J; Aebi, S; Karlsson, P; Neven, P; Hitre, E; Graas, M P; Simoncini, E; Abdi, E; Kamby, C; Thompson, A; Loibl, S; Gavilá, J; Kuroi, K; Marth, C; Müller, B; O'Reilly, S; Gombos, A; ... (2021). Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Annals of oncology, 32(10), pp. 1256-1266. Elsevier 10.1016/j.annonc.2021.07.017
Gennari, A; Sun, Z; Hasler-Strub, U; Colleoni, M; Kennedy, M J; Von Moos, R; Cortés, J; Vidal, M J; Hennessy, B; Walshe, J; Amillano Parraga, K; Ribi, K; Bernhard, Jürg; Morales, S Murillo; Pagani, O; Barbeaux, A; Borstnar, S; Rabaglio, Manuela; Maibach, R; Regan, M M; ... (2018). A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Annals of oncology, 29(3), pp. 661-668. Oxford University Press 10.1093/annonc/mdx772
